Chief Executive Officer & Co-Founder
Serial entrepreneur with 25 years of experience in technical products and venture development with disruptive innovations, globally. Biology degree from the University of California, Santa Cruz. Pioneered digital media industries with the first international ringtone business that generated over $1.5 billion in sales. Has raised over $33 million in venture financing for cutting-edge technology ventures and has led innovation projects for three Fortune 500 companies. Committed to the advancement of "organic" biomedical and life-enhancing initiatives.
Chairman & Co-Founder
Seasoned executive in the pharmaceutical and specialty chemical industries having led several businesses in the US, UK and South Africa, including regional divisions of Ciba-Geigy/Novartis and Rohm & Haas. Brought 17 pharmaceutical products to market. Successfully started up or turned around four companies. Degree in Chemical Engineering. Six years of local legal, commercial and regulatory review for international stem cell business projects. Leads the overall operations, production chain logistics, regulatory compliance and HR for the business.
Mitchell Silva, Ph.D.
Head of Bio-Systems, Clinical Trials & Patient Engagement
Establishes effective patient data collection and patient engagement strategies: designing patient data models, contextual analysis for input in AI/ML models, defining KPIs, writing SOPs to allow compliant data collection, organizing patient advisory boards to capture unmet needs, acquiring input to define research priorities. Provides tech platforms to acquire patient treatment, symptom management, and reporting. Chair of EUPATI Belgium which trains “patient experts” in the field of drug development with an international network, being one of the global HIMSS #Future50.
Ignatius Viljoen, IRCA, ICQ cGxP & Quality Specialist
A Chartered Quality Professional and Qualified Person in cGMP manufacturing environments, Ignatius is the founder of FutureHealth, a common Good <> Practice (cGxP) consultancy. He has more than 30 years’ experience in the international pharmaceutical industry. He had leadership roles in Ciba-Geigy, Novartis/Sandoz, Ranbaxy and Boehringer Ingelheim where he worked in Country and Regional Head roles. He has also worked on product and business development projects in multiple countries in Sub-Saharan Africa, Argentina, Brazil and Mexico, Malaysia, Philippines and Taiwan, Turkey and Russia.
Jonathan Lakey, PhD., MSM
Chairman, Science Advisory Board
Professor of Surgery and Biomedical Engineering and Director of Research and Clinical Islet Program at the University of California, Irvine’s prestigious Sue and Bill Gross Stem Cell Center. Specialist in biological devices for the implantation of pancreatic islets, differentiated stem cells and developing technologies including exosomes. Author of over 400 academic papers and over 40 book chapters with adjunct professorships and biotech engagements with leading research universities and biotechnology companies in several countries, Lakey is poised to be one of the world’s leading applied researchers in the treatment of diabetes with stem cells.